René Bruno (Rene Bruno)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 27

Top Topics

Decision Making

Ulcerative Colitis

Small Cell Lung Cancer

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

Clinical cancer research : an official journal of the American Association for Cancer Research

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Mathilde Marchand, Antonio Gonçalves, Francois Mercier, Pascal Chanu, Jin Yan Jin, Jeremie Guedj, René Bruno
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Sebastien Benzekry, Mélanie Karlsen, Célestin Bigarré, Abdessamad El Kaoutari, Bruno Gomes, Martin Stern, Ales Neubert, René Bruno, Francois Mercier, Suresh Vatakuti, Peter Curle, Candice Jamois
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers. Clinical pharmacology and therapeutics (2024)
Mathilde Marchand, Antonio Gonçalves, Francois Mercier, Pascal Chanu, Jin Yan Jin, Jeremie Guedj, René Bruno
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches. CPT: pharmacometrics & systems pharmacology (2024)
Mathilde Marchand, Antonio Gonçalves, Francois Mercier, Pascal Chanu, Jin Yan Jin, Jeremie Guedj, René Bruno
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Mathilde Marchand, Antonio Gonçalves, Francois Mercier, Pascal Chanu, Jin Yan Jin, Jeremie Guedj, René Bruno
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical pharmacology and therapeutics 113 (4) (2023)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical pharmacology and therapeutics 113 (4) (2023)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical pharmacology and therapeutics (2023)
Colby S Shemesh, Phyllis Chan, Mathilde Marchand, Antonio Gonçalves, Shweta Vadhavkar, Benjamin Wu, Chunze Li, Jin Y Jin, Stephen P Hack, René Bruno
Early decision making in a randomized phase II trial of atezolizumab in biliary tract cancer using a tumor growth inhibition-survival modeling framework. Clinical pharmacology and therapeutics (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (6) (2023)
René Bruno, Pascal Chanu, Matts Kågedal, Francois Mercier, Kenta Yoshida, Jérémie Guedj, Chunze Li, Ulrich Beyer, Jin Y Jin
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models. British journal of cancer (2023)
René Bruno, Pascal Chanu, Matts Kågedal, Francois Mercier, Kenta Yoshida, Jérémie Guedj, Chunze Li, Ulrich Beyer, Jin Y Jin
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models. British journal of cancer (2023)
Antonio Gonçalves, Mathilde Marchand, Phyllis Chan, Jin Yan Jin, Jeremie Guedj, René Bruno
Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer. CPT: pharmacometrics & systems pharmacology (2023)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate pharmacometric model to define the impact of second-line immuno-therapies on the survival outcome of IMpower131 study. Clinical pharmacology and therapeutics (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (6) (2023)
René Bruno, Pascal Chanu, Matts Kågedal, Francois Mercier, Kenta Yoshida, Jérémie Guedj, Chunze Li, Ulrich Beyer, Jin Y Jin
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models. British journal of cancer (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (6) (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Anita Moein, Tong Lu, Siv Jonsson, Jakob Ribbing, Nastya Kassir, Wenhui Zhang, Gizette Sperinde, Rong Zhang, Meina T Tang, Young S Oh, René Bruno, Rui Zhu
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis. CPT: pharmacometrics & systems pharmacology 11 (9) (2022)
Mathilde Marchand, Rong Zhang, Phyllis Chan, Valerie Quarmby, Marcus Ballinger, Nitzan Sternheim, Benjamin Wu, Jin Y Jin, René Bruno
Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer chemotherapy and pharmacology 88 (2) (2021)
Phyllis Chan, Mathilde Marchand, Kenta Yoshida, Shweta Vadhavkar, Nina Wang, Alyse Lin, Benjamin Wu, Marcus Ballinger, Nitzan Sternheim, Jin Y Jin, René Bruno
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework. CPT: pharmacometrics & systems pharmacology 10 (10) (2021)
Omid Hamid, René Bruno, Marcella Fasso, Carol O'Hear, Benjamin Wu
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (10) (2020)
René Bruno, Dean Bottino, Dinesh P de Alwis, Antonio T Fojo, Jérémie Guedj, Chao Liu, Kristin R Swanson, Jenny Zheng, Yanan Zheng, Jin Y Jin
Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (8) (2019)
Kari M Morrissey, Mathilde Marchand, Hina Patel, Rong Zhang, Benjamin Wu, H Phyllis Chan, Almut Mecke, Sandhya Girish, Jin Y Jin, Helen R Winter, René Bruno
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer chemotherapy and pharmacology 84 (6) (2019)
Coralie Tardivon, Solène Desmée, Marion Kerioui, René Bruno, Benjamin Wu, France Mentré, Francois Mercier, Jeremie Guedj
Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up. Clinical pharmacology and therapeutics 106 (4) (2019)
Laurent Claret, Christina Pentafragka, Sanja Karovic, Binsheng Zhao, Lawrence H Schwartz, Michael L Maitland, René Bruno
Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study. Cancer chemotherapy and pharmacology 82 (1) (2018)